Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I. Neven P, et al. Among authors: pelgrims g. Breast Cancer Res Treat. 2008 May;109(1):59-65. doi: 10.1007/s10549-007-9628-2. Epub 2007 Jun 26. Breast Cancer Res Treat. 2008. PMID: 17592772 Free article. Clinical Trial.
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group.
Vergote I, Van Nieuwenhuysen E, De Waele S, Vulsteke C, Lamot C, Van den Bulck H, Claes N, Graas MP, Debrock G, Spoormans I, Vuylsteke P, Honhon B, Verhoeven D, De Maeseneer D, Dirix L, Mebis J, Vroman P, Denys H, Martinez Mena C, Pelgrims G, Van Steenberghe M, van Gorp T, Gennigens C. Vergote I, et al. Among authors: pelgrims g. Int J Gynecol Cancer. 2022 Jun 6;32(6):753-760. doi: 10.1136/ijgc-2021-003190. Int J Gynecol Cancer. 2022. PMID: 35063943 Clinical Trial.
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N. Van Praet C, et al. Among authors: pelgrims g. Urol Oncol. 2016 Jun;34(6):254.e7-254.e13. doi: 10.1016/j.urolonc.2015.12.017. Epub 2016 Feb 2. Urol Oncol. 2016. PMID: 26850781
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N. Van Praet C, et al. Among authors: pelgrims g. Clin Genitourin Cancer. 2017 Aug;15(4):502-508. doi: 10.1016/j.clgc.2017.01.019. Epub 2017 Feb 1. Clin Genitourin Cancer. 2017. PMID: 28258960
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.